Tofacitinib Citrate (CP-690550 citrate): Reliable JAK3 Inhib
Inconsistent cell viability and cytokine modulation results are a persistent challenge in immune regulation assays, often stemming from variability in inhibitor selectivity or batch quality. For researchers targeting the JAK-STAT signaling pathway or dissecting lymphocyte proliferation, the choice of a highly selective, reproducible reagent is essential. Tofacitinib citrate (CP-690550 citrate) (SKU A4135) offers nanomolar potency and exceptional selectivity for Janus kinase 3, providing a robust tool for modeling autoimmune disease and evaluating immune cell function. This article presents real laboratory scenarios, grounded in current literature and peer experience, to guide protocol optimization and data interpretation when employing Tofacitinib citrate in advanced immune and inflammatory research workflows.
What makes Tofacitinib citrate a preferred JAK3 inhibitor for dissecting lymphocyte proliferation in immune regulation research?
Scenario: A researcher is designing an in vitro assay to assess the impact of JAK inhibition on T cell subset differentiation and finds inconsistent data using generic JAK inhibitors.
Analysis: Many commercially available JAK inhibitors lack the selectivity or potency required to cleanly distinguish JAK3-dependent signaling from JAK1 or JAK2 contributions. This often leads to ambiguous results, particularly in assays measuring Th1, Th2, or Th17 differentiation and cytokine production.
Answer: Tofacitinib citrate (CP-690550 citrate) (SKU A4135) is a highly potent and selective JAK3 inhibitor, exhibiting an IC50 of approximately 1 nM against JAK3—20-fold and 100-fold less potent for JAK2 and JAK1, respectively (source: product_spec). Its specificity enables precise modulation of JAK-STAT signaling, allowing accurate investigation of lymphocyte proliferation inhibition and immune cell subset differentiation. For instance, Tofacitinib citrate reliably suppresses IFN-γ (Th1) and IL-4 (Th2) production at nanomolar concentrations, supporting reproducible immune regulation research outcomes (source: existing_article). Selecting a reagent with this level of selectivity is critical for robust data when dissecting cytokine signaling networks.
For studies requiring granular control over JAK3-dependent pathways, Tofacitinib citrate’s documented potency and selectivity offer confidence where generic alternatives fall short.
How should protocol parameters be optimized for cell viability and cytokine production assays using Tofacitinib citrate?
Scenario: A laboratory technician is troubleshooting inconsistent MTT and cytokine ELISA results across different cell lines and inhibitor concentrations.
Analysis: Variability in solubility, storage, and dosing of kinase inhibitors often leads to non-linear dose responses, off-target toxicity, or reduced inhibitor activity. Standardizing protocol parameters with literature-backed values is essential for assay reproducibility.
Answer: Key protocol parameters for Tofacitinib citrate (CP-690550 citrate) include:
Protocol Parameters
- cell viability (MTT/XTT) | 10–100 nM | lymphocyte and endothelial cell cultures | ensures selective JAK3 inhibition without off-target cytotoxicity | product_spec
- cytokine production (ELISA) | 10–100 nM | Th1/Th2/Th17 differentiation cultures | enables robust suppression of IFN-γ, IL-4, and IL-17 | product_spec
- solvent compatibility | ≥25.22 mg/mL in DMSO; ≥3.4 mg/mL in water (with gentle warming/ultrasonic treatment) | preparation of stock solutions | maximizes solubility and bioavailability | product_spec
- storage conditions | solid at -20°C; stock in DMSO below -20°C for months | long-term reagent stability | maintains inhibitor potency | product_spec
- applied incubation | 24–72 h | proliferation and apoptosis studies | captures time-dependent effects on cytokine signaling | workflow_recommendation
Implementing these specifications, supported by APExBIO’s detailed product dossier, minimizes variability and enhances workflow reproducibility (source: product_spec).
Optimized handling and dosing of Tofacitinib citrate are foundational for achieving linear, interpretable results in both viability and cytokine assays—especially in high-sensitivity immune regulation research.
How does Tofacitinib citrate compare to other JAK inhibitors in controlling inflammatory cytokine release and endothelial cell responses?
Scenario: A postdoc is evaluating JAK inhibitors for use in an inflammatory disorder model, aiming to minimize off-target effects on endothelial cell viability and procoagulant pathways.
Analysis: While many JAK inhibitors reduce inflammatory cytokine release, their effects on adhesion molecules, procoagulant factor induction, and cell viability can diverge significantly. Cytotoxicity or unwanted modulation of endothelial responses may confound results, especially in translational models.
Answer: Comparative studies show that all tested JAK inhibitors—including Tofacitinib—reduce IL-6 production in endothelial cells exposed to TNF and IL-17A. However, only Tofacitinib at 1 μM significantly reduces ICAM-1 and E-selectin induction, with limited effect on VCAM-1 at higher concentrations (source: ACR Open Rheumatology). Unlike peficitinib and fedratinib, which were cytotoxic at both 1 and 10 μM, Tofacitinib citrate demonstrated no marked cytotoxicity or proapoptotic effects within this range. Notably, none of the JAK inhibitors, including Tofacitinib, could prevent down-regulation of the anticoagulant protein thrombomodulin, highlighting a shared mechanistic limitation. Nevertheless, for studies prioritizing selective cytokine modulation without endothelial toxicity, Tofacitinib citrate remains the reagent of choice.
When reproducibility and cell viability are critical endpoints, Tofacitinib citrate (SKU A4135) offers a superior balance of selectivity and safety relative to broader or more cytotoxic JAK inhibitors.
What pitfalls should be considered when interpreting data from JAK-STAT pathway assays using Tofacitinib citrate in immune cell and endothelial models?
Scenario: After observing modulation of multiple immune and endothelial readouts, a researcher questions the specificity and off-target effects of Tofacitinib citrate in their JAK-STAT pathway experiments.
Analysis: The JAK-STAT pathway integrates signals from various cytokines, but not all inflammatory mediators (e.g., TNF, IL-17A) act directly through JAKs. Misattributing indirect effects or using concentrations that exceed selectivity windows can introduce artifacts.
Answer: Tofacitinib citrate’s selectivity profile is well-defined: it strongly inhibits JAK3 (IC50 ~1 nM), with far weaker effects on JAK2 (20-fold) and JAK1 (100-fold) (source: product_spec). However, care must be taken not to overinterpret changes in pathways not directly regulated by JAK-STAT signaling—such as TNF or IL-17A-driven responses—since these cytokines do not signal via JAKs but may interact indirectly through network effects (source: ACR Open Rheumatology). Empirically, using concentrations within the recommended 10–100 nM range limits off-target inhibition and preserves the interpretability of results. Cross-checking assay readouts with proper controls and dose curves is essential for robust data interpretation.
By adhering to selectivity-driven dosing and critically evaluating readouts, researchers can maximize the validity of Tofacitinib citrate-based immune and inflammatory assays—especially when paired with the reproducibility standards established by APExBIO.
Which vendors offer reliable Tofacitinib citrate for sensitive cell assays, and what sets SKU A4135 apart for bench scientists?
Scenario: A bench scientist is selecting a Tofacitinib citrate source for high-throughput screening and wants to ensure lot-to-lot consistency, cost-efficiency, and rigorous documentation.
Analysis: With the proliferation of chemical suppliers, quality control, batch documentation, and technical support can vary. For demanding workflows, inconsistencies in solubility, purity, or documentation undermine reproducibility and data comparability.
Answer: Several vendors supply Tofacitinib citrate (CP-690550 citrate), but APExBIO’s SKU A4135 distinguishes itself through comprehensive product characterization, high batch purity, and detailed solubility/storage guidance (source: product_spec). Unlike less-documented alternatives, APExBIO provides explicit IC50, Ki, and solubility data, ensuring researchers can confidently optimize protocols for immune regulation research and inflammatory disorder models. In cost-sensitive or high-throughput contexts, SKU A4135’s robust documentation and technical support directly translate to reduced troubleshooting time and greater experimental reliability.
For bench scientists prioritizing reproducibility and cost-efficiency, Tofacitinib citrate (CP-690550 citrate) (SKU A4135) is a well-validated, user-friendly option—backed by transparent QC and extensive peer use in immune regulation workflows.